NO972273L - En ny, fysikalsk stabil, fast form av et fluorkinolon - Google Patents
En ny, fysikalsk stabil, fast form av et fluorkinolonInfo
- Publication number
- NO972273L NO972273L NO972273A NO972273A NO972273L NO 972273 L NO972273 L NO 972273L NO 972273 A NO972273 A NO 972273A NO 972273 A NO972273 A NO 972273A NO 972273 L NO972273 L NO 972273L
- Authority
- NO
- Norway
- Prior art keywords
- iii
- sample
- quinolone
- dsc
- form iii
- Prior art date
Links
- 239000007787 solid Substances 0.000 title description 11
- 229940124307 fluoroquinolone Drugs 0.000 title description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 30
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 29
- 239000013078 crystal Substances 0.000 claims description 25
- 238000002844 melting Methods 0.000 claims description 22
- 238000002441 X-ray diffraction Methods 0.000 claims description 21
- 230000008018 melting Effects 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 124
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- 239000011521 glass Substances 0.000 description 17
- 239000002904 solvent Substances 0.000 description 16
- 230000009466 transformation Effects 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000012453 solvate Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 238000001179 sorption measurement Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000001953 recrystallisation Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000004821 distillation Methods 0.000 description 6
- 238000002334 isothermal calorimetry Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000007704 transition Effects 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- -1 quinolone compound Chemical class 0.000 description 5
- 238000000844 transformation Methods 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011067 equilibration Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 4
- 150000004682 monohydrates Chemical class 0.000 description 4
- 150000007660 quinolones Chemical class 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000004320 controlled atmosphere Methods 0.000 description 3
- 239000012297 crystallization seed Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000004807 desolvation Methods 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 3
- 229960001180 norfloxacin Drugs 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- ZHJGWYRLJUCMRT-UHFFFAOYSA-N 5-[6-[(4-methylpiperazin-1-yl)methyl]benzimidazol-1-yl]-3-[1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide Chemical compound C=1C=CC=C(C(F)(F)F)C=1C(C)OC(=C(S1)C(N)=O)C=C1N(C1=C2)C=NC1=CC=C2CN1CCN(C)CC1 ZHJGWYRLJUCMRT-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241001507939 Cormus domestica Species 0.000 description 1
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 1
- 239000006004 Quartz sand Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000000892 gravimetry Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 238000001144 powder X-ray diffraction data Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003306 quinoline derived antiinfective agent Substances 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Developing Agents For Electrophotography (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34220294A | 1994-11-18 | 1994-11-18 | |
| PCT/US1995/013481 WO1996016055A1 (en) | 1994-11-18 | 1995-11-08 | A new physically stable solid form of a fluoroquinolone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO972273D0 NO972273D0 (no) | 1997-05-16 |
| NO972273L true NO972273L (no) | 1997-05-16 |
Family
ID=23340805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO972273A NO972273L (no) | 1994-11-18 | 1997-05-16 | En ny, fysikalsk stabil, fast form av et fluorkinolon |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5985893A (es) |
| EP (1) | EP0790992A1 (es) |
| JP (1) | JPH10509169A (es) |
| KR (1) | KR970707115A (es) |
| AU (1) | AU709057B2 (es) |
| BR (1) | BR9509688A (es) |
| CA (1) | CA2201735A1 (es) |
| CZ (1) | CZ138297A3 (es) |
| FI (1) | FI972103A0 (es) |
| HU (1) | HUT77946A (es) |
| MX (1) | MX9703622A (es) |
| NO (1) | NO972273L (es) |
| NZ (1) | NZ297590A (es) |
| PL (1) | PL320190A1 (es) |
| WO (1) | WO1996016055A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE43932E1 (en) | 1997-07-18 | 2013-01-15 | Novartis Ag | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
| CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| DE19854355A1 (de) | 1998-11-25 | 2000-05-31 | Bayer Ag | Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
| DE19854356A1 (de) | 1998-11-25 | 2000-05-31 | Bayer Ag | Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
| DE19908448A1 (de) * | 1999-02-26 | 2000-08-31 | Bayer Ag | Kristallmodifikation D von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo[4.3.0)nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino incarbonsäure |
| DE19908449A1 (de) | 1999-02-26 | 2000-08-31 | Bayer Ag | Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure |
| US6660864B2 (en) | 2001-06-29 | 2003-12-09 | Grayson Walker Stowell | Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
| US6596871B2 (en) | 2001-06-29 | 2003-07-22 | Grayson Walker Stowell | Polymorphic forms of 6-[4-(1-cyclohexyl-1h-tetraol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
| US6388080B1 (en) | 2001-06-29 | 2002-05-14 | Grayson Walker Stowell | Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
| US6531603B1 (en) | 2001-06-29 | 2003-03-11 | Grayson Walker Stowell | Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
| US6573382B2 (en) | 2001-06-29 | 2003-06-03 | Grayson Walker Stowell | Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
| US6657061B2 (en) | 2001-06-29 | 2003-12-02 | Grayson Walker Stowell | Polymorphic forms of 6-[4-1(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
| MX2007001811A (es) | 2004-08-13 | 2007-03-26 | Schering Plough Ltd | Formulacion farmaceutica que comprende un antibiotico, un triazol y un corticoesteroide. |
| US9481777B2 (en) | 2012-03-30 | 2016-11-01 | The Procter & Gamble Company | Method of dewatering in a continuous high internal phase emulsion foam forming process |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL63968A (en) * | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
| JP2676521B2 (ja) * | 1988-03-22 | 1997-11-17 | 北陸製薬株式会社 | キノロンカルボン酸化合物ｉ型結晶の製造法 |
| US5258528A (en) * | 1990-11-30 | 1993-11-02 | Warner-Lambert Company | Individual stereoisomers of pyrrolidine methanamines substituted on the ring nitrogen by a 1-phenylethyl group |
| EP0559774B1 (en) * | 1990-11-30 | 1999-07-07 | Warner-Lambert Company | Individual stereoisomers of 7- 3-(1-aminoalkyl)-1-pyrrolidinyl]-quinolones and naphthyridones as antibacterial agents |
| ES2167329T3 (es) * | 1992-01-31 | 2002-05-16 | Chugai Pharmaceutical Co Ltd | Cristal de hidrato de derivado de acido quinolonacarboxilico. |
-
1995
- 1995-11-08 AU AU42780/96A patent/AU709057B2/en not_active Ceased
- 1995-11-08 WO PCT/US1995/013481 patent/WO1996016055A1/en not_active Application Discontinuation
- 1995-11-08 JP JP8516848A patent/JPH10509169A/ja active Pending
- 1995-11-08 BR BR9509688A patent/BR9509688A/pt not_active Application Discontinuation
- 1995-11-08 HU HU9800950A patent/HUT77946A/hu unknown
- 1995-11-08 NZ NZ297590A patent/NZ297590A/en unknown
- 1995-11-08 EP EP95941328A patent/EP0790992A1/en not_active Ceased
- 1995-11-08 CZ CZ971382A patent/CZ138297A3/cs unknown
- 1995-11-08 MX MX9703622A patent/MX9703622A/es not_active Application Discontinuation
- 1995-11-08 CA CA002201735A patent/CA2201735A1/en not_active Abandoned
- 1995-11-08 PL PL95320190A patent/PL320190A1/xx unknown
-
1996
- 1996-05-01 US US08/641,569 patent/US5985893A/en not_active Expired - Fee Related
-
1997
- 1997-05-16 NO NO972273A patent/NO972273L/no not_active Application Discontinuation
- 1997-05-16 FI FI972103A patent/FI972103A0/fi unknown
- 1997-05-17 KR KR1019970703329A patent/KR970707115A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU709057B2 (en) | 1999-08-19 |
| BR9509688A (pt) | 1997-09-30 |
| HUT77946A (hu) | 1998-12-28 |
| AU4278096A (en) | 1996-06-17 |
| CA2201735A1 (en) | 1996-05-30 |
| JPH10509169A (ja) | 1998-09-08 |
| KR970707115A (ko) | 1997-12-01 |
| FI972103A (fi) | 1997-05-16 |
| WO1996016055A1 (en) | 1996-05-30 |
| PL320190A1 (en) | 1997-09-15 |
| FI972103A0 (fi) | 1997-05-16 |
| CZ138297A3 (en) | 1997-10-15 |
| MX9703622A (es) | 1997-08-30 |
| NO972273D0 (no) | 1997-05-16 |
| EP0790992A1 (en) | 1997-08-27 |
| NZ297590A (en) | 1999-06-29 |
| US5985893A (en) | 1999-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO972273L (no) | En ny, fysikalsk stabil, fast form av et fluorkinolon | |
| CN103958469B (zh) | 一种新的普利多匹定盐酸盐多晶型形态 | |
| MXPA97003622A (es) | Una nueva forma solida fisicamente estable en unafluoroquinolona | |
| Schinzer et al. | Characterization and interconversion of polymorphs of premafloxacin, a new quinolone antibiotic | |
| TW202110811A (zh) | Btk抑制劑之結晶形狀 | |
| KR20230118154A (ko) | 톨레브루티닙의 결정 형태, 이의 제조 방법 및 용도 | |
| EA020767B1 (ru) | Новые формы свободного основания бендамустина | |
| US20230357322A1 (en) | Method of manufacturing a pharmaceutical composition | |
| Stevenson et al. | The solid state forms of the sex hormone 17-β-estradiol | |
| TW202138346A (zh) | ７ｈ－苯並［７］輪烯－２－羧酸衍生物之晶形 | |
| Gabdulkhaev et al. | Smart control of calixarene polymorphic states | |
| Dash et al. | Solid-state properties of tobramycin | |
| TW201840557A (zh) | (s)-[2-氯-4-氟-5-(7-嗎啉-4-基喹唑啉-4-基)苯基]-(6-甲氧基-嗒𠯤-3-基)-甲醇之結晶型 | |
| Yang et al. | Thermodynamic stability analysis of m-nisoldipine polymorphs | |
| CN109897009B (zh) | 一种Apabetalone水合物晶型及其制备方法 | |
| EP2078014A2 (en) | Crystalline and amorphous forms of tiagabine | |
| Dash et al. | Solid-state characterization of AG337 (Thymitaq), a novel antitumor drug | |
| Dong et al. | Crystal structure and physical characterization of neotame methanol solvate | |
| Guguta et al. | The hydration/dehydration behavior of aspartame revisited | |
| Bates | Application of the Debye normalization procedure | |
| EP2064206A2 (en) | Crystalline forms of tiagabine hydrochloride and processes for the preparation of amorphous tiagabine hydrochloride | |
| EP1989183A1 (en) | Crystalline form of remifentanil hydrochloride | |
| WO2017060290A1 (en) | Crystalline encenicline hydrochloride | |
| CN1164231A (zh) | 氟代喹诺酮的新的物理稳定固体形式 | |
| EP2895469B1 (en) | Solid forms of (s)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid and of salts thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |